Literature DB >> 17680199

Intravenous phentolamine infusion alleviates the pain of abdominal visceral cancer, including pancreatic carcinoma.

Masako Yasukawa1, Ken'ichi Yasukawa, You Kamiizumi, Ryouji Yokoyama.   

Abstract

This case report series describes eight patients (four patients with pancreatic carcinoma, one patient with hepatocellular carcinoma, one patient with gastric and rectal carcinoma, one with sigmoid colon cancer, and one with rectal cancer), whose abdominal cancer pain was treated with intravenous phentolamine infusion at 80 mg x day(-1) for 2 days. All but one of the patients had already been treated with opioids. All eight patients complained of severe abdominal pain; in five patients the pain radiated to the back, and there was associated anal pain in two patients. Analgesia was achieved in three patients; pain alleviation was obtained in four patients, but was not sustained in two of these four patients; and the treatment in one patient could not be judged for efficacy because epidural morphine was used together with the phentolamine. Adverse effects of phentolamine were tachycardia and/or hypotension.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17680199     DOI: 10.1007/s00540-007-0528-8

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  7 in total

1.  Novel approaches to the treatment of neuropathic pain.

Authors:  R W Presley
Journal:  West J Med       Date:  1992-11

2.  Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression.

Authors:  Theodore H Lindsay; Beth M Jonas; Molly A Sevcik; Kazufumi Kubota; Kyle G Halvorson; Joseph R Ghilardi; Michael A Kuskowski; Edward B Stelow; Pinku Mukherjee; Sandra J Gendler; Gilbert Y Wong; Patrick W Mantyh
Journal:  Pain       Date:  2005-11-18       Impact factor: 6.961

3.  Intravenous phentolamine mesylate alleviates the pain of pancreatic carcinoma.

Authors:  Gary J McCleane
Journal:  Pain       Date:  1997-11       Impact factor: 6.961

4.  Monitoring adequacy of alpha-adrenoceptor blockade following systemic phentolamine administration.

Authors:  Srinivasa N Raja; Jennifer L Turnquist; Sherif Meleka; James N Campbell
Journal:  Pain       Date:  1996-01       Impact factor: 6.961

5.  Peak pain relief is delayed and duration of relief is extended following intravenous phentolamine infusion. Preliminary report.

Authors:  B S Galer
Journal:  Reg Anesth       Date:  1995 Sep-Oct

6.  Systemic alpha-adrenergic blockade with phentolamine: a diagnostic test for sympathetically maintained pain.

Authors:  S N Raja; R D Treede; K D Davis; J N Campbell
Journal:  Anesthesiology       Date:  1991-04       Impact factor: 7.892

7.  Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial.

Authors:  Gilbert Y Wong; Darrell R Schroeder; Paul E Carns; Jack L Wilson; David P Martin; Michelle O Kinney; Carlos B Mantilla; David O Warner
Journal:  JAMA       Date:  2004-03-03       Impact factor: 56.272

  7 in total
  2 in total

Review 1.  Road map for pain management in pancreatic cancer: A review.

Authors:  Marie José Lahoud; Hampig Raphael Kourie; Joelle Antoun; Lana El Osta; Marwan Ghosn
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

2.  Pain management in pancreatic cancer.

Authors:  Mariam Hameed; Haroon Hameed; Michael Erdek
Journal:  Cancers (Basel)       Date:  2010-12-24       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.